Tropisetron modulates peripheral and central serotonin/insulin levels: Via insulin and nuclear factor kappa B/receptor for advanced glycation end products signalling to regulate type-2 diabetes in rats

dc.AffiliationOctober University for modern sciences and Arts (MSA)
dc.contributor.authorMohamed R.A.
dc.contributor.authorGalal O.
dc.contributor.authorMohammed A.R.
dc.contributor.authorEl-Abhar H.S.
dc.contributor.otherDepartment of Pharmacology and Toxicology
dc.contributor.otherFaculty of Pharmacy
dc.contributor.otherOctober University for Modern Sciences and Arts (MSA)
dc.contributor.other26 July Mehwar Road Intersection with Wahat Road
dc.contributor.other6th October City Cairo
dc.contributor.other12566
dc.contributor.otherEgypt; Department of Pharmacology and Toxicology
dc.contributor.otherFaculty of Pharmacy
dc.contributor.otherCairo University
dc.contributor.otherCairo
dc.contributor.otherEgypt
dc.date.accessioned2020-01-09T20:41:07Z
dc.date.available2020-01-09T20:41:07Z
dc.date.issued2018
dc.descriptionScopus
dc.description.abstractDespite its known central effect, 5% of serotonin is found centrally, while around 95% is found peripherally. Serotonin is stored and co-released with insulin upon pancreatic islets stimulation by glucose. This fact raises the curiosity regarding its possible role in diabetes. Hence, in this study, we assessed the possible modulatory effects of tropisetron, a 5-HT3 receptor antagonist, on type 2 diabetes mellitus models in rats. The rats were allocated into two groups: normal and diabetic. The latter group was treated with metformin (500 mg kg-1, p.o.), tropisetron (1 and 2 mg kg-1, i.p.), and a combination of metformin and tropisetron (1 mg kg-1). The different treatment regimens corrected glucose and lipid homeostasis manifested by the decrease in serum levels of glucose, fructosamine, homeostasis model of insulin resistance, triglycerides, total cholesterol, free fatty acid, as well as receptor for advanced glycation end products. Additionally, the treatments elevated levels of insulin, serotonin, and homeostasis model of ?-cell function. On the molecular level, treatments corrected the altered insulin signaling cascade (phosphorylated insulin receptor substrate 1, phosphorylated protein kinase B, and glucose transporter 4), and inhibited ?-catenin and phosphorylated nuclear factor kappa B p65 in the assessed soleus skeletal muscle. A similar pattern was duplicated in the hippocampus. This study provided evidence for the role of tropisetron on type 2 diabetes mellitus via modulating the insulin signaling cascade (insulin, phosphorylated insulin receptor substrate 1, phosphorylated protein kinase B, and glucose transporter 4), improving lipid/glucose profile, decreasing inflammatory markers (receptor for advanced glycation end products, and phosphorylated nuclear factor kappa B p65), as well as increasing 5-HT and reducing ?-catenin. � The Royal Society of Chemistry 2018.en_US
dc.description.urihttps://www.scimagojr.com/journalsearch.php?q=21100199840&tip=sid&clean=0
dc.identifier.doihttps://doi.org/10.1039/c7ra13105d
dc.identifier.doiPubMed ID :
dc.identifier.issn20462069
dc.identifier.otherhttps://doi.org/10.1039/c7ra13105d
dc.identifier.otherPubMed ID :
dc.identifier.urihttps://t.ly/ve7Bq
dc.language.isoEnglishen_US
dc.publisherRoyal Society of Chemistryen_US
dc.relation.ispartofseriesRSC Advances
dc.relation.ispartofseries8
dc.subjectEnzymesen_US
dc.subjectFatty acidsen_US
dc.subjectGlucoseen_US
dc.subjectGlycosylationen_US
dc.subjectPhosphorylationen_US
dc.subjectPhysiologyen_US
dc.subjectRatsen_US
dc.subjectAdvanced glycation end productsen_US
dc.subjectDifferent treatmentsen_US
dc.subjectGlucose transporter 4en_US
dc.subjectInsulin receptor substrate 1en_US
dc.subjectNuclear factor kappaBen_US
dc.subjectPhosphorylated proteinsen_US
dc.subjectReceptor antagonistsen_US
dc.subjectType 2 diabetes mellitusen_US
dc.subjectInsulinen_US
dc.titleTropisetron modulates peripheral and central serotonin/insulin levels: Via insulin and nuclear factor kappa B/receptor for advanced glycation end products signalling to regulate type-2 diabetes in ratsen_US
dc.typeArticleen_US
dcterms.isReferencedByTseung, J., (2005) Pathology, 37, p. 190; Azevedo, M., Alla, S., (2008) Int. J. Diabetes Dev. Countries, 28, pp. 101-108; (2014) Diabetes Care, 37, pp. S81-S90; Donath, M.Y., Shoelson, S.E., (2011) Nat. Rev. Immunol., 11, pp. 98-107; Robertson, R.P., Harmon, J., Tran, P.O.T., Poitout, V., (2004) Diabetes, 53, pp. S119-S124; Hull, R.L., Westermark, G.T., Westermark, P., Kahn, S.E., (2004) J. Clin. Endocrinol. Metab., 89, pp. 3629-3643; Kelley, D.E., He, J., Menshikova, E.V., Ritov, V.B., (2002) Diabetes, 51, pp. 2944-2950; Seaquist, E.R., (2010) Diabetes, 59, pp. 4-5; Gupta, D., Thangaraj, D., Radhakrishnan, M., (2016) Behav. Brain Res., 297, pp. 41-50; Zemdegs, J., Quesseveur, G., Jarriault, D., P�nicaud, L., Fioramonti, X., Guiard, B.P., (2015) Br. J. Pharmacol., 173, pp. 2095-2110; Gold, S., Dziobek, I., Sweat, V., Tirsi, A., Rogers, K., Bruehl, H., Tsui, W., Convit, A., (2007) Diabetologia, 50, pp. 711-719; Paulmann, N., Grohmann, M., Voigt, J.-P., Bert, B., Vowinckel, J., Bader, M., Skelin, M., Rupnik, M., (2009) PLoS Biol., 7, p. e1000229; Mechlovich, D., Amit, T., Bar-Am, O., Weinreb, O., Youdim, M.B., (2014) Br. J. Pharmacol., 171, pp. 5636-5649; El-Marasy, S.A., Abdallah, H.M., El-Shenawy, S.M., El-Khatib, A.S., El-Shabrawy, O.A., Kenawy, S.A., (2014) Can. J. Physiol. Pharmacol., 92, pp. 945-952; Nicole, E., Barry, E.J., Pinelli, C., Wood, G.A., Hardy, D.B., Morrison, K.M., Taylor, V.H., Holloway, A.C., (2015) Toxicol. Appl. Pharmacol., 285, pp. 32-40; Iwabayashi, M., Taniyama, Y., Azuma, J., Sanada, F., Iekushi, K., Rakugi, H., Morishita, R., (2013) Biochemical Basis and Therapeutic Implications of Angiogenesis, pp. 225-238. , Springer; Amireault, P., Sibon, D., C�t�, F., (2012) ACS Chem. Neurosci., 4, pp. 64-71; Bouwens, L., Rooman, I., (2005) Physiol. Rev., 85, pp. 1255-1270; Rieck, S., White, P., Schug, J., Fox, A.J., Smirnova, O., Gao, N., Gupta, R.K., Keller, M.P., (2009) Mol. Endocrinol., 23, pp. 1702-1712; Kim, H., Toyofuku, Y., Lynn, F.C., Chak, E., Uchida, T., Mizukami, H., Fujitani, Y., Kosaka, Y., (2010) Nat. Med., 16, pp. 804-808; Heimes, K., Feistel, B., Verspohl, E.J., (2009) Eur. J. Pharmacol., 624, pp. 58-65; Vleugels, R., Verlinden, H., Vanden Broeck, J., (2015) Neurotransmitter, 2, pp. 1-14; Costall, B., Naylor, R.J., (2004) CNS Neurol. Disord.: Drug Targets, 3, pp. 27-37; Tecott, L.H., Maricq, A.V., Julius, D., (1993) Proc. Natl. Acad. Sci., 90, pp. 1430-1434; Motavallian, A., Minaiyan, M., Rabbani, M., Andalib, S., Mahzouni, P., (2013) Bioimpacts, 3, pp. 169-176; Dupont, L., Pype, J., Demedts, M., De Leyn, P., Deneffe, G., Verleden, G., (1999) Eur. Respir. J., 14, pp. 642-649; Fiebich, B., Akundi, R., Lieb, K., Candelario-Jalil, E., Gmeiner, D., Haus, U., M�ller, W., Munoz, E., (2004) Scand. J. Rheumatol., 33, pp. 28-32; Fakhfouri, G., Rahimian, R., Ghia, J.-E., Khan, W.I., Dehpour, A.R., (2012) Drug Discovery Today, 17, pp. 741-747; Schaalan, M., El-Abhar, H.S., Barakat, M., El-Denshary, E.S., (2009) J. Diabetes Complications, 23, pp. 199-208; Saleh, S., El-Maraghy, N., Reda, E., Barakat, W., (2014) An. Acad. Bras. Cienc., 86, pp. 1935-1948; Khan, H.B.H., Vinayagam, K.S., Moorthy, B.T., Palanivelu, S., Panchanatham, S., (2013) Inflammopharmacology, 21, pp. 37-46; El-Abhar, H.S., Schaalan, M.F., (2012) PLoS One, 7, p. e37757; Boyda, H.N., Procyshyn, R.M., Asiri, Y., Wu, C., Wang, C.K., Lo, R., Pang, C.C., Barr, A.M., (2014) Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 48, pp. 170-176; Rahimian, R., Daneshmand, A., Mehr, S.E., Barzegar-Fallah, A., Mohammadi-Rick, S., Fakhfouri, G., Shabanzadeh, A.P., Dehpour, A.R., (2011) Brain Res., 1392, pp. 101-109; Matthews, D., Hosker, J., Rudenski, A., Naylor, B., Treacher, D., Turner, R., (1985) Diabetologia, 28, pp. 412-419; Astrup, A., Finer, N., (2000) Obesity Rev., 1, pp. 57-59; Richmond, J., Codignola, A., Cooke, I., Sher, E., (1996) Pfl�gers Archiv, 432, pp. 258-269; Rohrer, S., Menge, B.A., Gr�ber, L., Deacon, C.F., Schmidt, W.E., Veldhuis, J.D., Holst, J.J., Meier, J.J., (2012) J. Clin. Endocrinol. Metab., 97, pp. E791-E795; Nolan, C.J., Damm, P., Prentki, M., (2011) J.-Lancet, 378, pp. 169-181; Tab�k, A.G., Jokela, M., Akbaraly, T.N., Brunner, E.J., Kivim�ki, M., Witte, D.R., (2009) J.-Lancet, 373, pp. 2215-2221; Skovs�, S., (2014) J. Diabetes Invest., 5, pp. 349-358; Carvalho, F., Barros, D., Silva, J., Rezende, E., Soares, M., Fregoneze, J., De Castro-E-Silva, E., (2005) Horm. Metab. Res., 37, pp. 482-488; Kennedy, L., Baynes, J., (1984) Diabetologia, 26, pp. 93-98; Suzuki, D., Toyoda, M., Yamamoto, N., Miyauchi, M., Katoh, M., Kimura, M., Maruyama, M., Yagame, M., (2006) Intern. Med., 45, pp. 435-441; Abo-Elmatty, D.M., Essawy, S.S., Badr, J.M., Sterner, O., (2013) J. Ethnopharmacol., 145, pp. 269-277; Donath, M.Y., Gross, D.J., Cerasi, E., Kaiser, N., (1999) Diabetes, 48, pp. 738-744; Mackenzie, R., Trulson, M., (1978) J. Neurochem., 30, pp. 205-211; Malyszko, J., Urano, T., Knofler, R., Taminato, A., Yoshimi, T., Takada, Y., Takada, A., (1994) Thromb. Res., 75, pp. 569-576; Marti, F., Mi, J., Aldegunde, M., Atienza, G., (1994) Life Sci., 56, pp. 51-59; Fernstrom, J.D., Wurtman, R., (1971) Science, 173, pp. 149-152; Manjarrez, G., Nishimura, E., Hernandez, J., (2003) J. Pediatr. Neurol., 28, pp. 20-23; Ahmad, S., Tabassum, S., Haider, S., (2013) J. Pak. Med. Assoc., 63, pp. 65-68; Madras, B., Cohen, E., Fernstrom, J., Larin, F., Munro, H., Wurtman, R., (1973) Nature, 244, pp. 34-35; Madras, B.K., Cohen, E.L., Messing, R., Munro, H.N., Wurtman, R.J., (1974) Metabolism, 23, pp. 1107-1116; Curzon, G., Marsden, C., (1975) J. Neurochem., 25, pp. 251-256; Cangiano, C., Laviano, A., Del Ben, M., Preziosa, I., Angelico, F., Cascino, A., Rossi-Fanelli, F., (1998) Int. J. Obes., 22, pp. 648-654; Atienza, G., Andres, M., Rebolledo, E., Aldegunde, M., (1992) Neurochem. Res., 17, pp. 289-292; Russo, S., Kema, I.P., Fokkema, R.M., Boon, J.C., Willemse, P.H., De Vries, E.G., Den Boer, J.A., Korf, J., (2003) Psychosom. Med., 65, pp. 665-671; Fierabracci, V., Novelli, M., Ciccarone, A., Masiello, P., Benzi, L., Navalesi, R., Bergamini, E., (1996) Diabetes Metab., 22, pp. 51-56; Hwang, I., Ha, H., (2009) Arch. Pharmacal Res., 32, pp. 1653-1662; Rooney, B., O'Donovan, H., Gaffney, A., Browne, M., Faherty, N., Curran, S.P., Sadlier, D., Crean, J., (2011) FEBS Lett., 585, pp. 531-538; (2011) Chinese Journal of Diabetes, 19, pp. 149-151; Liu, W., Liang, X., Yang, D., (2015) Evid.-Based Complement. Altern. Med., 501, p. 295135; Sun, X.-L., Liu, Y., Shi, M.-H., Zhong, W., Hong, Z., Yang, H., Sen, S., He, Y.-Z., (2011) Chinese Journal of Endocrinology and Metabolism, 27, pp. 57-61; (2012) Chinese Journal of Blood Purification, 11, pp. 33-37; Jang, J., Ha, J.-H., Chung, S.-I., Yoon, Y., (2014) Int. J. Mol. Med., 34, pp. 632-638; Jang, J., Ha, J.-H., Kim, S.-M., Kim, W., Kim, K., Chung, S.-I., Yoon, Y., (2014) Mol. Med. Rep., 9, pp. 633-638; Soubh, A.A., Abdallah, D.M., El-Abhar, H.S., (2015) Life Sci., 136, pp. 142-150; Ho, Y.-J., Chen, W.-P., Chi, T.-C., Chang Chien, C., Lee, A.-S., Chiu, H.-L., Kuo, Y.-H., Su, M.-J., (2013) Cardiovasc. Diabetol., 12, pp. 99-110; Amin, M.M., Asaad, G.F., Salam, R.M.A., El-Abhar, H.S., Arbid, M.S., (2014) PLoS One, 9, p. e89169; Cubeddu, L., B�nisch, H., G�thert, M., Molderings, G., Racke, K., Ramadori, G., Miller, K., Schw�rer, H., (2000) Naunyn-Schmiedeberg's Arch. Pharmacol., 361, pp. 85-91; Miller, A.D., Nonaka, S., (1992) J. Pharmacol. Exp. Ther., 260, pp. 509-517; Hawthorn, J., Ostler, K., Andrews, P., (1988) Q. J. Exp. Physiol., 73, pp. 7-21; Cubeddu, L.X., Hoffmann, I.S., Fuenmayor, N.T., Finn, A.L., (1990) N. Engl. J. Med., 322, pp. 810-816; Fuangchan, A., Sonthisombat, P., Seubnukarn, T., Chanouan, R., Chotchaisuwat, P., Sirigulsatien, V., Ingkaninan, K., Haines, S.T., (2011) J. Ethnopharmacol., 134, pp. 422-428; Tanaka, Y., Uchino, H., Shimizu, T., Yoshii, H., Niwa, M., Ohmura, C., Mitsuhashi, N., Kawamori, R., (1999) Eur. J. Pharmacol., 376, pp. 17-22; Isoda, K., Young, J.L., Zirlik, A., Macfarlane, L.A., Tsuboi, N., Gerdes, N., Sch�nbeck, U., Libby, P., (2006) Arterioscler., Thromb., Vasc. Biol., 26, pp. 611-617; Markowska, A., Pawa?owska, M., Filas, V., Korski, K., Grybo?, M., Sajdak, S., Olejek, A., Lubin, J., (2013) Diabetol. Metab. Syndr., 5, pp. 76-87; Patan�, G., Piro, S., Rabuazzo, A.M., Anello, M., Vigneri, R., Purrello, F., (2000) Diabetes, 49, pp. 735-740
dcterms.sourceScopus

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
avatar_scholar_128.png
Size:
2.73 KB
Format:
Portable Network Graphics
Description:
Loading...
Thumbnail Image
Name:
c7ra13105d.pdf
Size:
1.17 MB
Format:
Adobe Portable Document Format
Description: